The Effect of Zoledronic Acid Combined with Percutaneous Kyphoplasty on the Treatment of Osteoporotic Vertebral Body Compression Fractures in Patients

Our study aims to investigate the clinical efficacy of zoledronic acid combined with percutaneous kyphoplasty (PKP) on the treatment of Osteoporotic vertebral compression fractures (OVCF). 102 OVCF patients were enrolled and randomly divided into two groups (Group A and Group B). Group A was given postoperative placebo, and group B was treated with zoledronic acid after operation. The pain visual analogue scale (VAS), vertebral bone mineral density (BMD), and adverse effects were compared between the two groups. Tartrate acid phosphonate (TRACP) 5b, type I collagen C-terminal peptide (CTX) levels were determined. The result showed that preoperative and postoperative VAS scores after 1, 3, 6, and 12 months in group B were significantly lower than group A while the BMD in group B was higher than that in group A (P < 0.05). TRACP 5b and CTX decreased at 1, 3, 6, and 12 months after surgery, and the level in group B was significantly reduced compared to that in group A (P < 0.05). In conclusion, zoledronic acid, combined with PKP, can improve the therapeutic efficacy of OVCF after surgery, which provides new insights for the further treatment of OVCF in clinical practice.